|drug451||Beck Depression Inventory (BDI) Wiki||1.00|
There is one clinical trial.
Emergent experimental and anecdotal evidence has indicated that critically ill COVID-19 patients demonstrate two patient sub-types (called phenotypes). In one group the disease progresses slowly and patients have a low potential of developing mild respiratory failure, but in the other group, an exaggerated immune response (hyper-inflammation/cytokine storm) may be linked to the onset of precipitous respiratory failure, termed acute respiratory distress syndrome. This syndrome is responsible for a large portion of COVID-19 associated mortality. Thus, determining links between hyper-inflammation and acute respiratory distress syndrome in COVID-19 patients is of immediate importance. Blood samples will undergo a number of analyses to help us to understand as much as possible about COVID-19. We will also study any differences in physiologic and cytokine levels before and after patients are treated with immunomodulatory therapies as part of clinical care in COVID-19 patients.
Description: Interleukin 1b, 6, 10 and tumor necrosis factor alphaMeasure: Inflammation Time: 24 hours
Description: Ratio of arterial oxygen tension (mmHg) to fraction of inspired oxygen (PaO2/FiO2)Measure: Oxygenation Time: 24 hours
Description: Pulmonary function tests (forced vital capacity (ml))Measure: Chronic Pulmonary outcomes Time: 8 to 12 weeks after discharge
Description: Pulmonary artery pressure (mmHg)Measure: Pulmonary artery pressure using transthoracic echocardiography Time: 8 to 12 weeks after discharge
Description: 6-minute walk testMeasure: Exertion Time: 8 to 12 weeks after discharge
Description: Short Form 36 (range 0 - 100)Measure: Quality of life assessment Time: 8 to 12 weeks after discharge
Description: Ventilator free daysMeasure: Duration of mechanical ventilation Time: 30 days
Data processed on September 26, 2020.